In a letter this week to its suppliers, McKesson—the largest pharmaceutical distributor in the United States—addressed their expectations relating to ...

While increased healthcare spend will likely lead to higher revenues for manufacturers, life sciences companies will focus heavily on addressing ...

Launching a new, undifferentiated drug in a mature and highly regulated market can be challenging—even for an established organization. Facing the ...

The leadership team of a multinational healthcare company was dissatisfied with the organization’s ability to realize true value from its large scale. ...

As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...

Developing data strategies for the storage, analysis and protection of patient-specific data has never been more critical to the future ...

Many nations have enacted serialization regulations to combat counterfeit products and diversions of legitimate pharmaceutical products, and those that have not are planning ...

The global regulatory landscape is continuously evolving to protect patients and ensure supply chain visibility. Companies will need flexible implementation plans and increasingly agile ...

To explore our 2015 Life Sciences Trends Report, download the PDF here or view an abbreviated overview below. In 2015, ...

Over the last two years, Clarkston Consulting has released its study on Quality in Generic Pharmaceuticals. As in the past, ...

As populations in emerging markets grow and their economies improve, so will the demand for quality, affordable health care. In ...

An article published this month in New York Magazine highlights the recent advancements to the regenerative medicine and medical device ...